West China Hospital of Stomatology, Sichuan University
Chengdu, 610041, China
NCT Number: NCT06195137
The aim of this study was to evaluate the efficacy of caffeine and alpha-lipoic acid in the treatment of burning mouth syndrome by symptom assessment with visual analogue scale.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Chengdu, 610041, China
The etiology of BMS is multifactorial, involving a complex interplay of neuropathic, psychological, neuroendocrine, and immunological factors. Neurologically, BMS has been categorized into three subtypes: peripheral small fiber neuropathy, subclinical trigeminal neuropathy, and inhibitory dopaminergic deficiency. Neuroimaging and peripheral nerve studies have further implicated altered brain activation patterns and increased expression of specific receptors like TRPV1 and P2X3 in the pathogenesis of BMS. Hormonal imbalances, particularly in estrogen levels, have also been suggested to contribute to contribute to the condition.
Caffeine, a xanthine alkaloid chemically known as 1,3,7-trimethylxanthine, is recognized for its diverse biological functions. As a central nervous system stimulant, its primary mechanism involves antagonizing adenosine receptors, thereby enhancing the release of neurotransmitters such as dopamine and norepinephrine, which are known to play roles in analgesic pathways. Caffeine is also noted for its neuroprotective properties and is theorized to reduce the risk of neurodegenerative diseases. It affects the central processing of pain and is involved in regulating circadian rhythms and sleep-wake cycles. Additionally, caffeine has mild anti-inflammatory properties. Its stimulatory effects may also improve mood and cognitive function.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
caffeine supplementation
600-800 mg ALA
Other names: ALA
Time frame: Baseline and 2 weeks after intervention or observation
During the interview or telephone follow-up with the patient, ask the patient to fill in the VAS rating scale.
Lu Jiang
Other
Efficacy of Caffeine vs. Alpha-Lipoic Acid in Burning Mouth Syndrome Treatment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07711665
Caffeine, Placebo - Control
Alcalá de Henares, Madrid, Spain
View Trial DetailsNCT07711652
Caffeine, Placebo
Alcalá de Henares, Madrid, Spain
View Trial DetailsNCT07333443
Caffeine, Climbing
Alcalá de Henares, Madrid, Spain
View Trial DetailsNCT07386899
Caffeine
Izmir, Bornova, Turkey (Türkiye)
View Trial Details